PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Study for MR Formulation of PF-06650833 in Healthy Adult Japanese Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: placebo
Drug: PF-06650833

First Posted Date: 2016-10-18

Last Posted Date: 2018-10-05

Lead Sponsor: Pfizer

Target Recruit Count: 10

Registration Number: NCT02936154

Locations: 🇯🇵
P-one Clinic, Keikokai Medical Corporation, Hachioji-shi, Tokyo, Japan

Efficacy and Safety Study of Enzalutamide in Combination With Paclitaxel Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative Breast Cancer

Phase 3

Withdrawn

Conditions: Breast Cancer

Interventions: Drug: Placebo
Drug: Enzalutamide
Drug: Paclitaxel

First Posted Date: 2016-10-11

Last Posted Date: 2018-10-22

Lead Sponsor: Pfizer

Registration Number: NCT02929576

Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer

Phase 3

Completed

Conditions: BRAF V600E-mutant Metastatic Colorectal Cancer

Interventions: Drug: Encorafenib
Drug: Binimetinib
Drug: Irinotecan
Drug: Cetuximab
Drug: Folinic Acid
Drug: 5-Fluorouracil

First Posted Date: 2016-10-10

Last Posted Date: 2023-12-21

Lead Sponsor: Pfizer

Target Recruit Count: 702

Registration Number: NCT02928224

Locations: 🇺🇸
The University of Kansas Cancer Center, Investigational Drug Services, Westwood, Kansas, United States
🇧🇷
Hospital do Olho, Salvador, Bahia, Brazil
🇦🇹
DZU, Diagnose Zentrum Urania GmbH, Wien, Austria

and more 404 locations

National Observational Study On The Use Of Inflectra™ An Infliximab Biosimilar In Real Life

Completed

Conditions: Ankylosing Spondylitis
Psoriatic Arthritis
Ulcerative Colitis
Rheumatoid Arthritis
Crohn Disease

Interventions: Other: QOL questionaire

First Posted Date: 2016-10-05

Last Posted Date: 2023-01-25

Lead Sponsor: Pfizer

Target Recruit Count: 1431

Registration Number: NCT02925338

Locations: 🇫🇷
Centre Hospitalier, Metz Tessy, France
🇫🇷
Hopital Saint Philibert, Lomme, France
🇫🇷
Hopitaux Universitaires de Strasbourg - Hopital de Hautepierre, Strasbourg, Alsace, France

and more 62 locations

A Study in Healthy Volunteers to Assess Immune Response to Multiple Injections of Filgrastim Hospira or Neupogen Reference Product.

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Biological: Filgrastim Hospira
Biological: US-Approved Neupogen

First Posted Date: 2016-10-05

Last Posted Date: 2017-02-23

Lead Sponsor: Pfizer

Target Recruit Count: 256

Registration Number: NCT02923791

Locations: 🇺🇸
SeaView Research, Inc., Miami, Florida, United States
🇺🇸
Seaview Jacksonville LLC, Jacksonville, Florida, United States

Clinical Outcome Of Hormonal Receptor Positive, Her-2 Negative Breast Cancer In Taiwan

Completed

Conditions: ER/PR(+), Her2(-) Breast Cancer

First Posted Date: 2016-10-05

Last Posted Date: 2018-06-14

Lead Sponsor: Pfizer

Target Recruit Count: 1

Registration Number: NCT02924584

Locations: 🇨🇳
National Cheng Kung University, Tainan City, Taiwan

Open-Label Extension and Safety Study of Talazoparib

Phase 2

Completed

Conditions: Cancer

Interventions: Drug: Talazoparib

First Posted Date: 2016-10-03

Last Posted Date: 2022-08-24

Lead Sponsor: Pfizer

Target Recruit Count: 120

Registration Number: NCT02921919

Locations: 🇺🇸
UCLA Hematology/Oncology - Burbank, Burbank, California, United States
🇺🇸
TRIO-US Central Administration, Los Angeles, California, United States
🇺🇸
UCLA Hematology/Oncology, Los Angeles, California, United States

and more 33 locations

A Safety And Efficacy Study of Ibuprofen 250 mg / Acetaminophen 500 mg In The Treatment Of Post-Surgical Dental Pain

Phase 3

Completed

Conditions: Post-surgical Pain Following Extraction of Molar Teeth

Interventions: Drug: Acetaminophen 650 mg
Drug: Ibuprofen 250 mg
Drug: Placebo
Drug: Ibuprofen 250 mg / Acetaminophen 500 mg

First Posted Date: 2016-09-23

Last Posted Date: 2017-08-30

Lead Sponsor: Pfizer

Target Recruit Count: 568

Registration Number: NCT02912650

Locations: 🇺🇸
Jean Brown Research, Salt Lake City, Utah, United States

An Open-label Extension Study To Evaluate Safety Of PF-06252616 In Boys With Duchenne Muscular Dystrophy

Phase 2

Terminated

Conditions: Duchenne Muscular Dystrophy

Interventions: Biological: PF-06252616

First Posted Date: 2016-09-20

Last Posted Date: 2020-11-23

Lead Sponsor: Pfizer

Target Recruit Count: 59

Registration Number: NCT02907619

Locations: 🇨🇦
Alberta Children's Hospital, Calgary, Alberta, Canada
🇨🇦
CHU Sainte-Justine, Montreal, Quebec, Canada
🇯🇵
National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan

and more 44 locations

Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides

Phase 1

Terminated

Conditions: Melanoma
Merkel-cell Carcinoma
Breast Carcinoma
Squamous Cell Carcinoma
Solid Tumors
Mycosis Fungoides
Human Papillomavirus-Related Malignant Neoplasm
Soft Tissue Sarcoma

Interventions: Other: TTI-621 + T-Vec
Drug: TTI-621 Monotherapy
Other: TTI-621 + radiation
Drug: TTI-621 + PD-1/PD-L1 Inhibitor
Drug: TTI-621 + pegylated interferon-α2a

First Posted Date: 2016-09-07

Last Posted Date: 2023-04-05

Lead Sponsor: Pfizer

Target Recruit Count: 56

Registration Number: NCT02890368

Locations: 🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
🇺🇸
University of Washington - Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸
City of Hope National Medical Center, Duarte, California, United States

and more 4 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy